- Key Takeaways
- Influencing Evidence Before It Is Fixed
- Health Economics and Evidence Fluency
- Payer Landscape Knowledge Is Market-Specific
- Pricing Judgment and Cross-Functional Influence
- What This Looks Like in Practice
- The Mistake Employers Keep Making
- Narrow vs Strong Market Access Leadership
- The Bottom Line
- Related Reading
- Frequently Asked Questions
Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. Market access determines whether a drug that works reaches the patients who need it, and the VP leading it operates at the intersection of evidence, economics, policy, and commercial strategy. The best market access leaders shape evidence generation years before launch rather than presenting a value story after the data is fixed, and that difference is what separates strong candidates from experienced ones.
Key Takeaways
- Great market access leaders influence evidence strategy early, not late.
- Health economics and payer evidence fluency is the core capability.
- Payer landscape knowledge is market-specific and not fully transferable.
- Pricing strategy judgment carries long-term consequences.
- The role requires influence across medical, commercial, and regulatory.
Influencing Evidence Before It Is Fixed
The distinguishing characteristic of a strong market access leader is that they shape what evidence gets generated, working with clinical development to ensure trials produce the comparators, endpoints, and subgroup data that payers will require, rather than being handed a dataset at the end and asked to build a value story from it. By the time a pivotal trial is designed, most of the access outcome is determined. Candidates who describe having influenced development decisions for access reasons are operating at the level the role requires; those who describe building dossiers from completed data are describing a narrower job.
Health Economics and Evidence Fluency
The technical core of the role is health economic and outcomes evidence: understanding how cost-effectiveness models are built and critiqued, what real-world evidence can and cannot support, how comparative effectiveness arguments are constructed, and what different payer systems weigh. A VP need not personally build models, but must be able to direct the work, judge its quality, and defend it under scrutiny. Assess this substantively rather than accepting general familiarity, since the difference between a leader who genuinely understands the evidence and one who manages people who do is significant.
Payer Landscape Knowledge Is Market-Specific
Access environments differ enormously between markets: the US commercial and government payer landscape, national health technology assessment systems, and regional or hospital-level decision-making in other markets each operate on different logic. Experience in one does not automatically transfer to another. For a company launching in specific markets, prioritise candidates with genuine experience in those environments over broader but shallower international exposure, since the relationships, precedents, and tactical judgment are market-specific.
Pricing Judgment and Cross-Functional Influence
Pricing decisions made at launch constrain everything afterward, and the market access leader is central to them, balancing access breadth, revenue, reference pricing implications across markets, and long-term sustainability. This requires judgment rather than analysis alone. The role also depends on influence: market access has no authority over clinical development or commercial strategy but must shape both, so candidates need the credibility and relational skill to be heard early rather than consulted late. Assess how the candidate has actually built that influence.
What This Looks Like in Practice
A pharmaceutical company hiring a VP of Market Access looks for candidates who have genuinely influenced evidence generation before trials were designed, assesses health economic and evidence fluency substantively, prioritises experience in the specific markets it is launching into, and evaluates the candidate’s demonstrated ability to influence clinical and commercial colleagues without authority.
The Mistake Employers Keep Making
The most common mistake is hiring market access as a downstream function, someone to build the dossier and negotiate once the data exists, and structuring the role so it engages late. This guarantees that the evidence will have gaps payers care about, and no amount of skill afterward fully compensates. The company mistakes market access for a launch activity rather than a development-stage discipline.
Narrow vs Strong Market Access Leadership
| Narrow Version | Strong Version |
|---|---|
| Builds dossiers from completed data | Shapes trial design for payer requirements |
| Manages HEOR staff | Directs and judges evidence strategy |
| General international exposure | Deep knowledge of target markets |
| Executes pricing decisions | Exercises pricing judgment with long-term view |
| Consulted at launch | Influential during development |
The Bottom Line
A great VP of Market Access shapes evidence generation years before launch, brings genuine health economic fluency, knows the specific payer environments you are entering, and holds enough cross-functional credibility to be heard during development rather than consulted at launch. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see How to Recruit a Chief Medical Officer for a Pharma Company, Recruiting for Rare Disease and Orphan Drug Companies, Building an Executive Team for a Pre-Commercial Biotech.
Frequently Asked Questions
- Q: What distinguishes a strong market access leader?
- A: Influencing what evidence gets generated during development, working with clinical teams on comparators, endpoints, and subgroups that payers require, rather than building a value story after data is fixed.
- Q: What technical capability does the role require?
- A: Health economic and outcomes evidence fluency, understanding how cost-effectiveness models are built and critiqued, what real-world evidence supports, and what different payer systems weigh.
- Q: Does payer experience transfer between markets?
- A: Only partly; US commercial and government payers, HTA systems, and hospital-level decision-making operate on different logic, so market-specific experience matters for your launch markets.
- Q: Why does pricing judgment matter so much?
- A: Because launch pricing constrains everything afterward, including reference pricing implications across markets, so it requires judgment about long-term sustainability rather than analysis alone.
- Q: What is the common structural mistake?
- A: Treating market access as a downstream launch function that engages after data exists, which guarantees evidence gaps payers care about that later skill cannot fully repair.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
